Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Blood Cancer J. 2018 Feb 12;8(2):16. doi: 10.1038/s41408-018-0055-x.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors*
  • Enzyme Inhibitors / administration & dosage*
  • Enzyme Inhibitors / adverse effects
  • Female
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / enzymology
  • Humans
  • Lymphoproliferative Disorders / drug therapy*
  • Lymphoproliferative Disorders / enzymology
  • Male
  • Middle Aged
  • Recurrence

Substances

  • Enzyme Inhibitors
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CD protein, human